1-20 of 30
William D. Tap
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma

Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B. Banks, Jason Chan, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Ciara M. Kelly, Mary L. Keohan, Robert Maki, Evan Rosenbaum, Tiffany Salcito, Kaithleen Rodriguez, Rebecca Dempsey, Paul A. Meyers, Seth M. Cohen, Martee L. Hensley, Jason A. Konner, Alison M. Schram, Robert A. Lefkowitz, Joseph P. Erinjeri, Li-Xuan Qin, William D. Tap, Sandra P. D’Angelo
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5612–5619.
https://doi.org/10.1158/1078-0432.CCR-24-2519
Published: 16 December 2024
View article titled, Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Open the PDF for Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma in another window
Includes: Supplementary data
Journal Articles

GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression

Silvia Stacchiotti, Silvia Martini, Sandro Pasquali, Anna M. Frezza, Alessia Beretta, Stefano Percio, Mara Lecchi, Monica Tortoreto, Marta Barisella, Paola Collini, Gian Paolo Dagrada, Alessandra Merlini, Paul H. Huang, Andrew Jenks, Robin L. Jones, William D. Tap, Matilde Ingrosso, Carlo Morosi, Silvia Brich, Claudia Giani, Paolo Verderio, Paolo G. Casali, Hugh Leonard, Alessandro Gronchi, Valentina Zuco, Nadia Zaffaroni
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5122–5137.
https://doi.org/10.1158/1078-0432.CCR-23-3991
Published: 15 November 2024
View article titled, GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
Open the PDF for GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression in another window
Includes: Supplementary data
Journal Articles

The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations

Josephine K. Dermawan, David H. Abramson, Sarah Chiang, Martee L. Hensley, William D. Tap, Sujana Movva, Robert G. Maki, Diana Mandelker, Cristina R. Antonescu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4780–4790.
https://doi.org/10.1158/1078-0432.CCR-24-1160
Published: 15 October 2024
View article titled, The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Open the PDF for The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations in another window
Includes: Supplementary data
Journal Articles

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni A. Razak, Matthew H. Taylor, Todd M. Bauer, Breelyn Wilky, Javier Martin-Broto, Alejandro F. Gonzalez, Piotr Rutkowski, Bartlomiej Szostakowski, Thierry Alcindor, Ramy Saleh, Sofia Genta, Silvia Stacchiotti, Michiel van de Sande, Andrew J. Wagner, Nicholas Bernthal, Lara E. Davis, Jacqueline Vuky, Christopher Tait, Bahar Matin, Supraja Narasimhan, Maitreyi G. Sharma, Rodrigo Ruiz-Soto, Matthew L. Sherman, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3996–4004.
https://doi.org/10.1158/1078-0432.CCR-24-0103
Published: 13 September 2024
View article titled, CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Open the PDF for CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib in another window
Includes: Supplementary data
Journal Articles

Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal, Philip J. Ebert, Andrew J. Wagner, Jennifer Wright, Javier Martin-Broto, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2598–2608.
https://doi.org/10.1158/1078-0432.CCR-23-3936
Published: 03 June 2024
View article titled, Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Open the PDF for Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE in another window
Includes: Supplementary data
Journal Articles

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma

Josephine K. Dermawan, Sarah Chiang, Samuel Singer, Bhumika Jadeja, Martee L. Hensley, William D. Tap, Sujana Movva, Robert G. Maki, Cristina R. Antonescu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2260–2271.
https://doi.org/10.1158/1078-0432.CCR-24-0148
Published: 15 May 2024
View article titled, Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma
Open the PDF for Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Caroline E. Gleason, Mark A. Dickson, Mary E. Klein (Dooley), Cristina R. Antonescu, Rodrigo Gularte-Mérida, Marimar Benitez, Juliana I. Delgado, Raghu P. Kataru, Mark Wei Yi Tan, Martina Bradic, Travis E. Adamson, Kenneth Seier, Allison L. Richards, Marta Palafox, Eric Chan, Sandra P. D'Angelo, Mrinal M. Gounder, Mary Louise Keohan, Ciara M. Kelly, Ping Chi, Sujana Movva, Jonathan Landa, Aimee M. Crago, Mark T.A. Donoghue, Li-Xuan Qin, Violetta Serra, Mesruh Turkekul, Afsar Barlas, Daniel M. Firester, Katia Manova-Todorova, Babak J. Mehrara, Marta Kovatcheva, Nguan Soon Tan, Samuel Singer, William D. Tap, Andrew Koff
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 703–718.
https://doi.org/10.1158/1078-0432.CCR-23-2378
Published: 16 February 2024
View article titled, Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Open the PDF for Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma in another window
Includes: Supplementary data
Journal Articles

Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era

Josephine K. Dermawan, Ciara Kelly, Zhidong Gao, Shaleigh Smith, Bhumika Jadeja, Samuel Singer, William D. Tap, Ping Chi, Cristina R. Antonescu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3974–3985.
https://doi.org/10.1158/1078-0432.CCR-23-1184
Published: 02 October 2023
View article titled, Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Open the PDF for Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era in another window
Includes: Supplementary data
Journal Articles

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Patrick Schöffski, Rastislav Bahleda, Andrew J. Wagner, Melissa A. Burgess, Niels Junker, Michael Chisamore, Patrick Peterson, Anna M. Szpurka, Matteo Ceccarelli, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3320–3328.
https://doi.org/10.1158/1078-0432.CCR-23-0742
Published: 01 September 2023
View article titled, Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Open the PDF for Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Ciara M. Kelly, Li-Xuan Qin, Karissa A. Whiting, Allison L. Richards, Viswatej Avutu, Jason E. Chan, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Sujana Movva, Benjamin A. Nacev, Evan Rosenbaum, Travis Adamson, Samuel Singer, Edmund K. Bartlett, Aimee M. Crago, Sam S. Yoon, Sinchun Hwang, Joseph P. Erinjeri, Cristina R. Antonescu, William D. Tap, Sandra P. D'Angelo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2043–2051.
https://doi.org/10.1158/1078-0432.CCR-22-3911
Published: 01 June 2023
View article titled, A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Open the PDF for A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma in another window
Includes: Supplementary data
Journal Articles

Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)

Lee D. Cranmer, Yao Lu, Rachel S. Heise, Karla V. Ballman, Elizabeth T. Loggers, Seth M. Pollack, Michael J. Wagner, Denise K. Reinke, Patrick Schöffski, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1068–1076.
https://doi.org/10.1158/1078-0432.CCR-22-1564
Published: 14 March 2023
View article titled, Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <em>Post Hoc</em> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Open the PDF for Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <em>Post Hoc</em> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406) in another window
Includes: Supplementary data
Journal Articles

Abstract B022: Subclonal somatic copy number alterations emerge and dominate in relapsed/refractory osteosarcoma

Michael D. Kinnaman, Simone Zaccaria, Alvin Makohon-Moore, Gunes Gundem, Juan E. Arango Ossa, Nancy Bouvier, Filemon S. Dela Cruz, Meera Hameed, Julia Lynne Glade Bender, William D. Tap, Paul Meyers, Elli Papaemmanuil, Andrew Kung, Christine A. Iacobuzio-Donahue
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): B022.
https://doi.org/10.1158/1557-3265.SARCOMAS22-B022
Published: 15 September 2022
View article titled, Abstract B022: Subclonal somatic copy number alterations emerge and dominate in relapsed/refractory osteosarcoma
Journal Articles

Abstract B023: Prospective clinical genomic profiling of ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biological and therapeutic relevance

Arielle Elkrief, Koichi Ogura, Anita S. Bowman, Richard P. Koche, Ryma Benayed, Audrey Mauguen, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Paul A. Meyers, John H. Healey, William D. Tap, Neerav Shukla, Meera Hameed, Ahmet Zehir, Charles Sawyers, Rohit Bose, Emily Slotkin, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): B023.
https://doi.org/10.1158/1557-3265.SARCOMAS22-B023
Published: 15 September 2022
View article titled, Abstract B023: Prospective clinical genomic profiling of ewing sarcoma: <em>ERF</em> and <em>FGFR1</em> mutations as recurrent secondary alterations of potential biological and therapeutic relevance
Journal Articles

Abstract B008: Investigating the evolution of undifferentiated soft tissue sarcomas in a genetically engineered mouse model

Jason E. Chan, Jonathan Rub, Carleigh Sussman, Olivera Grbovic-huezo, William D. Tap, Cristina Antonescu, Sam Singer, Doron Betel, Tuomas Tammela
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): B008.
https://doi.org/10.1158/1557-3265.SARCOMAS22-B008
Published: 15 September 2022
View article titled, Abstract B008: Investigating the evolution of undifferentiated soft tissue sarcomas in a genetically engineered mouse model
Journal Articles

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

Laura M. Madanat-Harjuoja, Kelly Klega, Yao Lu, David S. Shulman, Aaron R. Thorner, Anwesha Nag, William D. Tap, Denise K. Reinke, Lisa Diller, Karla V. Ballman, Suzanne George, Brian D. Crompton
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2579–2586.
https://doi.org/10.1158/1078-0432.CCR-21-3951
Published: 13 June 2022
View article titled, Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Open the PDF for Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

Ping Chi, Li-Xuan Qin, Niedzica Camacho, Ciara M. Kelly, Sandra P. D'Angelo, Mark A. Dickson, Mrinal M. Gounder, Mary L. Keohan, Sujana Movva, Benjamin A. Nacev, Evan Rosenbaum, Katherine A. Thornton, Aimee M. Crago, Jasmine H. Francis, Moriah Martindale, Haley T. Phelan, Matthew D. Biniakewitz, Cindy J. Lee, Samuel Singer, Sinchun Hwang, Michael F. Berger, Yu Chen, Cristina R. Antonescu, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1507–1517.
https://doi.org/10.1158/1078-0432.CCR-21-3909
Published: 14 April 2022
View article titled, Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
Open the PDF for Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Mrinal M. Gounder, Evan Rosenbaum, Nian Wu, Mark A. Dickson, Tahir N. Sheikh, Sandra P. D'Angelo, Ping Chi, Mary Lou Keohan, Joseph P. Erinjeri, Cristina R. Antonescu, Narasimhan Agaram, Meera R. Hameed, Moriah Martindale, Robert A. Lefkowitz, Aimee M. Crago, Sam Singer, William D. Tap, Naoko Takebe, Li-Xuan Qin, Gary K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1586–1594.
https://doi.org/10.1158/1078-0432.CCR-21-3874
Published: 14 April 2022
View article titled, A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma
Open the PDF for A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma

Nicholas D. Klemen, Sinchun Hwang, Martina Bradic, Evan Rosenbaum, Mark A. Dickson, Mrinal M. Gounder, Ciara M. Kelly, Mary L. Keohan, Sujana Movva, Katherine A. Thornton, Ping Chi, Benjamin A. Nacev, Jason E. Chan, Edmund K. Bartlett, Allison L. Richards, Samuel Singer, Mark T.A. Donoghue, William D. Tap, Sandra P. D'Angelo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 939–947.
https://doi.org/10.1158/1078-0432.CCR-21-3445
Published: 01 March 2022
View article titled, Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
Open the PDF for Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma in another window
Includes: Supplementary data
Journal Articles

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 298–307.
https://doi.org/10.1158/1078-0432.CCR-21-2007
Published: 15 January 2022
View article titled, Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Open the PDF for Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT in another window
Includes: Supplementary data
Journal Articles

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Robin L. Jones, Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine, Javier Martín-Broto, Patrick M. Peterson, Jennifer Wright, William D. Tap
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3861–3866.
https://doi.org/10.1158/1078-0432.CCR-20-4592
Published: 15 July 2021
View article titled, Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Open the PDF for Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial in another window
Includes: Supplementary data